USP7 and neoplasm: Since USP7 inhibitors are developed primarily for oncology (Zhou et al., 2018), a more viable approach to use USP7 inhibitors as senolytic agents may be to clear SnCs induced by chemotherapy because such cells can contribute to chemotherapy‐induced toxicity and promote tumor relapse and metastasis in part via the SASP.